Cure8 research brief
The study suggests nickel accumulation and iron deficiency may be linked with more severe IBD. If confirmed, blood metal and micronutrient levels could help researchers understand disease mechanisms and guide nutritional assessment in people with IBD.
Clinicians who manage IBD, researchers studying environmental or nutritional contributors to IBD, and adult patients interested in micronutrient status and environmental exposures.
This single-center retrospective cross-sectional study measured serum levels of selected heavy metals (nickel, aluminum) and trace elements (iron, zinc, selenium, ferritin, vitamin D) in 137 patients with IBD (90 UC, 47 CD) versus 60 healthy controls and examined correlations with CRP, ESR, and fecal calprotectin.
The authors report higher nickel levels and evidence of iron deficiency associated with greater IBD severity; other measured metals/micronutrients showed no independent relationship. The brief is grounded in the article abstract provided.
This is a single-center, retrospective cross-sectional study using stored samples; associations do not prove causation. The abstract-level summary is based on the article text provided and does not include full study details such as statistical adjustment, effect sizes, or potential confounders.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Vitamin D supplementation is commonly considered in people with IBD because deficiency is frequent and low vitamin D may relate to inflammation.
People with IBD and their clinicians want ways to predict which advanced therapy will work best. This review summarizes current evidence and shows that, despite many studies, no biomarker is reliably ready for routine...
Noninvasive blood biomarkers that track IBD activity could reduce reliance on repeat endoscopy. If validated, serum galectin‑3 might complement fecal calprotectin and CRP to help identify active disease.
